# STOP-HAE: A Phase 3 Study of ADX-324 in HAE

> **NCT06960213** · PHASE3 · RECRUITING · sponsor: **ADARx Pharmaceuticals, Inc.** · enrollment: 90 (estimated)

## Conditions studied

- Hereditary Angioedema
- HAE
- Hereditary Angioedema - Type 1
- Hereditary Angioedema - Type 2

## Interventions

- **DRUG:** ADX-324
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06960213
- **Lead sponsor:** ADARx Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-28
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06960213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06960213, "STOP-HAE: A Phase 3 Study of ADX-324 in HAE". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06960213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*